Updated 6 November 2026. This article covers the 2025 debate; the subsequent legal position is explained separately.
Medical cannabis returned to Latvia’s political agenda in spring 2025. The State Police chief indicated that doctor-controlled use could be considered if medical experts regarded it as justified. This was not support for general legalisation, but was a notable contribution to the debate.
What did the police say?

On 21 February 2025, State Police chief Armands Ruks told journalists he opposed general drug-use decriminalisation. However, if medical experts identified a therapeutic need and doctors prescribed cannabis, he would not object in principle.
On 13 May 2025, the police reiterated that position to LETA: no support for general decriminalisation, but possible acceptance of controlled medical use if professional evidence supported it and doctors prescribed it. They noted that other tightly controlled psychotropic substances already have medical uses.
This was conditional openness to medical cannabis, rather than a call to legalise recreational use. An alleged direct quotation and conference reference in an earlier version could not be traced to a reliable original source and have been removed.
Why did the issue return in 2025?
In April 2025, Progresīvie decided to advance a proposal for doctor-supervised cannabis medicines, such as capsules, tablets or extracts. It cited patients with chronic pain, muscle spasms and chemotherapy-related nausea. Whether a particular treatment is appropriate depends on evidence, formulation and clinical judgement.
On 12 May 2025, Prime Minister Evika Siliņa said the coalition had no consensus on medical cannabis legalisation. New Unity wanted consultation with medical professionals; the Union of Greens and Farmers was not ready to support the proposal. Progresīvie said it would continue the discussion.
Is medical cannabis permitted in Latvia in 2026?
As of November 2026, Latvia had not established general access to prescribed cannabis flower, resin or extracts. These fall under its Schedule I controls, which prohibit ordinary handling. The plant must nevertheless be distinguished from separately regulated medicines containing particular cannabinoids, whose status may differ. It would therefore be inaccurate to say every medical use of every cannabinoid is prohibited without exception.
Latvian legislation sets out the controlled-substance lists and handling rules. Amendments adopted in February 2026 did not amount to general medical cannabis legalisation. A new general access system could not be confirmed as of 6 November 2026.
Why does the debate matter?
Latvia illustrates an important distinction: a person or authority can support tightly controlled medical access while opposing general decriminalisation. For patients, the question is access to quality-controlled, evidence-based treatment for appropriate indications. For supporters of prohibition, preventing misuse and diversion remains central.
420Eesti believes medical cannabis regulation deserves open, evidence-based debate. Confusing punishment with treatment does not help patients. Benefits and risks must nevertheless be evaluated for specific medicines and conditions, rather than presenting cannabis as a universal cure.
Read also: Cannabis Laws in Estonia in 2026 and Denmark’s Medical Cannabis Programme.
Sources
LETA / NRA: police chief’s position, 21 February 2025; LETA / The Baltic Times: police position, 13 May 2025; Latvian public broadcaster LSM: coalition debate, 12 May 2025; Latvian law on lawful handling of controlled substances; Latvian controlled-substance schedules.
